Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Pacira BioSciences (NASDAQ: PCRX) announced its participation in two upcoming healthcare conferences. The company will engage in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 19th at 3:00 PM GMT (10:00 AM ET).

Additionally, Pacira BioSciences will be present at the 36th Annual Piper Sandler Healthcare Conference on December 3rd at 1:00 PM ET. Interested parties can access live audio of these events on the “Events” page of the company’s website at investor.pacira.com. Replays will be available for two weeks following the events.

11/12/2024 - 08:00 AM

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

Jefferies London Healthcare Conference on Tuesday, November 19^th at 3:00PM GMT (10:00AM ET).
36^th Annual Piper Sandler Healthcare Conference on Tuesday, December 3^rd at 1:00PM ET.

Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.

About Pacira
Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.